公众号 / 文章重症综合管理与镇静镇痛消化、代谢与肾脏急症

重症监护病房中的益生菌治疗:一篇叙述性综述

Probiotic treatment in an intensive care unit: a narrative review.
PubMed 文献 · J Intensive Care · 2025-06-05
一句话结论2024年日本重症监护营养指南基于菌株、剂量等高度异质性,对重症患者益生菌使用给出弱推荐(GRADE 2C;低确定性)。

该叙述性综述聚焦重症患者腹泻与菌群失调问题,指出腹泻常由抗生素、抗酸药等药物诱发,并可增加艰难梭菌感染(CDI)和呼吸机相关性肺炎(VAP)风险。益生菌作为活的有益微生物,可能通过调节免疫、恢复微生物平衡和减轻肠道炎症来预防腹泻及继发感染;临床试验和荟萃分析显示其可能降低VAP发生率、ICU住院时间、机械通气时间和院内死亡率。但疗效评估受缺乏标准化标志物及抗酸药等混杂因素影响,且罕见不良事件如益生菌相关菌血症已有报告,尤其见于免疫抑制个体。2024年日本重症监护营养指南纳入系统评价和荟萃分析,支持益生菌在重症患者的潜在获益,但因菌株、剂量、疗程及合并用药高度异质性,给出弱推荐(GRADE 2C;低确定性)。未来研究应聚焦腹泻和菌群变化的标准化评估、客观标志物(如粪便pH和短链脂肪酸水平)及益生菌与其他药物相互作用的阐明。

要点

  • 2024年日本重症监护营养指南对重症患者使用益生菌给出弱推荐(GRADE 2C;低确定性),原因是菌株、剂量、疗程及合并抗生素/抗酸药使用高度异质性。
  • 临床试验和荟萃分析显示,益生菌可能降低重症患者VAP发生率、ICU住院时间、机械通气时间和潜在院内死亡率。
  • 益生菌相关菌血症等罕见不良事件已有报告,尤其见于免疫抑制个体。
  • 重症患者腹泻常由抗生素和抗酸药等药物诱发,可导致营养不良、电解质紊乱和脱水,并增加CDI和VAP风险。
  • 未来研究应标准化腹泻和菌群变化评估,使用粪便pH和短链脂肪酸水平等客观标志物,并阐明益生菌与其他药物的相互作用。

适用人群与场景

  • 重症患者,包括需要机械通气的ICU患者。
  • 免疫抑制个体使用益生菌时需注意罕见不良事件风险。

处置流程与药物剂量

  • 作者认为,全面的肠道管理,包括谨慎使用抗生素和抗酸药,可能对充分认识益生菌在重症监护中的治疗潜力至关重要。

红旗征与不能漏的情况

  • 益生菌相关菌血症等罕见不良事件已有报告,尤其见于免疫抑制个体。

研究设计与关键结果

  • 临床试验和荟萃分析显示,益生菌可能降低重症患者VAP发生率、ICU住院时间、机械通气时间和潜在院内死亡率。
  • 一项随机对照试验中,合生元治疗与粪便微生物群改善和感染减少相关,但该研究未涉及抗酸药的作用。
  • 2024年日本重症监护营养指南纳入系统评价和荟萃分析,支持益生菌在重症患者的潜在获益,但因菌株、剂量、疗程及合并抗生素/抗酸药使用高度异质性,给出弱推荐(GRADE 2C;低确定性)。

证据类型、等级与局限

  • 证据类型:叙述性综述。
  • 2024年日本重症监护营养指南基于系统评价和荟萃分析给出弱推荐(GRADE 2C;低确定性)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 2024年日本重症监护营养指南对重症患者使用益生菌给出弱推荐(GRADE 2C;低确定性),临床决策需考虑菌株、剂量、疗程及合并抗生素/抗酸药使用的异质性。
  • 作者认为,全面的肠道管理,包括谨慎使用抗生素和抗酸药,可能对充分认识益生菌在重症监护中的治疗潜力至关重要。
  • 对免疫抑制个体,需警惕益生菌相关菌血症等罕见不良事件。

指南或共识出处

  • 2024年日本重症监护营养指南

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Diarrhea is common in critically ill patients and can lead to malnutrition, electrolyte imbalance, and dehydration. While its direct impact on outcomes, such as mortality or intensive care unit (ICU) stay, remains unclear due to inconsistent definitions, it often results from drug-induced causes, such as antibiotics and antacids. These agents can also contribute to dysbiosis and increase the risk of infections including Clostridioides difficile infections (CDI) and ventilator-associated pneumonia (VAP).Probiotics, defined as live beneficial microorganisms, can counteract dysbiosis by modulating immune responses, restoring microbial balance, and reducing intestinal inflammation. Evidence suggests that probiotics may help prevent diarrhea and secondary infections. Clinical trials and meta-analyses have shown that probiotics may reduce the incidence of VAP, length of ICU stay, duration of mechanical ventilation, and potential in-hospital mortality in critically ill patients.However, evaluating probiotic efficacy remains challenging due to the lack of standardized markers and the influence of confounding factors like antacid use. In a randomized controlled trial, synbiotic therapy was associated with improved fecal microbiota and reduced infections; however, the role of antacids was not addressed.Probiotics are generally safe, although rare adverse events, such as probiotic-associated bacteremia, have been reported, particularly in immunocompromised individuals.The 2024 Japanese Critical Care Nutrition Guidelines included a systematic review and meta-analysis supporting the potential benefits of probiotics in critically ill patients. However, due to significant heterogeneity in strains, dosing, duration, and concurrent antibiotic/antacid use, a weak recommendation (GRADE 2C; low certainty) was issued.Future research should focus on the standardized evaluation of diarrhea and microbiota changes, the use of objective markers-such as fecal pH and short-chain fatty acid levels-and clarification of the interactions of probiotics with other medications. Comprehensive bowel management, including the cautious use of antibiotics and antacids, may be essential to fully recognize the therapeutic potential of probiotics in critical care settings.

来源:J Intensive Care,查看原文。版权归原作者所有。

参考来源

  1. Takeaki S. Probiotic treatment in an intensive care unit: a narrative review. J Intensive Care. 2025. PMID: 40474303. doi:10.1186/s40560-025-00803-0

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。